Aligos Therapeutics
ALGS
39 hedge funds and large institutions have $30.1M invested in Aligos Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 5 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
57% more capital invested
Capital invested by funds: $19.2M → $30.1M (+$10.9M)
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
11% more funds holding
Funds holding: 35 → 39 (+4)
0.02% less ownership
Funds ownership: 2.55% → 2.53% (-0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.7M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$4.2M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.98M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$1.68M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$892K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$914K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$783K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$443K |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$278K |
| 5 |
Millennium Management
New York
|
-$43.4K |
ALGS Hedge Fund Activity: Q4 2023 in Review
39 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q4 2023, worth a combined $30.1M — up 57% from $19.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ALGS positions and 5 closed out — a net gain of 4 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.7M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $914K sold.
- 39 institutional investors held Aligos Therapeutics (ALGS) as of Q4 2023, up from 35 in Q3 2023.
- Funds reported $30.1M of Aligos Therapeutics stock for Q4 2023, up 57% quarter-over-quarter.
- 9 funds opened new Aligos Therapeutics positions in Q4 2023 and 5 closed out, a net change of +4 holders.
- The largest Aligos Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $4.7M added.
- The largest Aligos Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $914K sold.
Based on aggregated 13F filings for Q4 2023.